BACKGROUND: @entity0 is one of the most common @entity5 diagnosed during pregnancy. Pregnancy-associated @entity0 (PABC) is defined as @entity0 diagnosed during pregnancy or within 12 months of delivery. Nowadays PABC can be safely diagnosed, staged, and treated during pregnancy with good outcomes for both the mother and the fetus. Recent studies suggest that prognosis of @entity1 diagnosed during postpartum seems to be worse. In order to gain a better understanding of the PABC, we reviewed our centre's experience. @entity1 AND METHODS: We assessed the clinicopathological parameters, evolution, and outcome of @entity1 treated in the Fundaci  n Instituto Valenciano de Oncolog  a of Valencia, Spain, from October 1990 to October 2013, and compared the results of @entity1 diagnosed during pregnancy (group 'A') and @entity1 diagnosed within one year of delivery (group 'B'). Of 12,000 cases of @entity0 registered in our database, 35 cases of PABC were identified. We included 11 @entity1 in group 'A' and 24 in group 'B'. RESULTS: In our group the median age was 35 years (range 29-42), of which ten (28%) @entity1 had family history (first grade) of @entity0 , four @entity1 were @entity5345 mutation carriers. Axillary node compromise was found in 19 @entity1 (53.5%), 24 @entity1 were stage II or III at diagnosis (68.5%), 22 (62.8%) were ER positive, and nine (25.7%) were @entity1722 positive. In group A (n = 11), five @entity1 diagnosed before 18th week decided that a therapeutic abortion be performed before treatment, two @entity1 were treated during pregnancy, one with chemotherapy without treatment associated complications during delivery. Four @entity1 diagnosed after 28th week decided to delay the treatment until delivery. After a follow up of 172 months, the relapse free survival (RFS) was 69% at five years and 45% at ten years. @entity1349 ( @entity1349 ) at five years was 90.8% and 74.2% at ten years for all @entity1 . For group 'A' @entity1349 was higher with 90% at five years versus 80% in group 'B'. The differences between the groups were not statistically significant p = 0.368. CONCLUSION: In our experience, there is a higher @entity1349 in @entity1 diagnosed during pregnancy suggesting a better prognosis for this group of @entity1 but the difference between the groups is not statistically significant. Our study is limited because of our small sample.

XXXX in pregnancy: an institutional experience.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'PATIENTS'] @entity0 :: ('MESH:D001943', 'Disease') :: ['Breast cancer', 'breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers'] @entity5345 :: ('672', 'Gene') :: ['BRCA 1'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'Overall survival'] @entity1722 :: ('2064', 'Gene') :: ['HER-2']
@entity0 :: (MESH:D001943,Disease) :: ['Breast cancer']
